MediWound Ltd. MDWD 深 沪
等待开盘 04-01 09:30:00 美东时间
16.11
+0.650
+4.20%
华盛通- 最 高16.24
- 今 开15.68
- 成交量 7.24万股
- 最 低 15.59
- 昨 收 15.46
- 总市值 2.07亿
- 52周最高 22.505
- 市盈率 静 --
- 换手率 0.56%
- 52周最低 14.90
- 委 比 0.00%
- 总股本 1284.57万
- 历史最高 135.17
- 量 比 0.65
- 振 幅 4.20%
- 历史最低 7.10
- 每 手 1
- 风险率 1.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MediWound Files Annual Report on Form 20-F
MediWound Ltd., a global leader in enzymatic therapeutics for tissue repair,has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the SEC on March 5, 2026. The report is available on the SEC’s website and the company’s investor relations site. Shareholders can request a hard copy free of charge. MediWound’s FDA-approved product, NexoBrid®, is used for enzymatic removal of eschar in thermal burns and is markete...
03-05 21:30
MediWound Affirms FY2026 Sales Guidance of $24.000M-$26.000M
MediWound (NASDAQ:MDWD) affirms FY2026 sales outlook from $24.000 million-$26.000 million to $24.000 million-$26.000 million.
03-05 21:26
MediWound Publishes Corporate Presentation on Next-Generation Enzymatic Therapies for Non-Surgical Tissue Repair
MediWound Publishes Corporate Presentation on Next-Generation Enzymatic Therapies for Non-Surgical Tissue Repair MediWound Ltd. released a company presentation highlighting its enzymatic therapeutics platform for non-surgical tissue repair, featuring NexoBrid and the investigational candidate Eschar
03-05 20:32
MediWound Q4 revenue falls 68% to USD 1.9 million
MediWound Q4 revenue falls 68% to USD 1.9 million MediWound said FY 2025 revenue was USD 17.0 million, with gross profit of USD 3.3 million (19.2% gross margin), operating loss of USD 25.3 million and net loss of USD 23.9 million (USD 2.10 per share). For Q4 2025, revenue was USD 1.9 million, gross
03-05 20:04
Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
What to Expect from MediWound's Earnings
MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on ...
03-05 04:02
Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility
Vericel Corporation received FDA approval to begin commercial production of MACI in its new Burlington facility, supporting capacity expansion and potential international commercialization.
03-04 13:00
Vericel to Present at Multiple Upcoming Investor Conferences
Vericel Corporation will present at TD Cowen's 46th Annual Healthcare Conference on March 4, 2026, and at Leerink Partners' 2026 Global Healthcare Conference on March 10, 2026. The presentations will be available online. Vericel, a leader in advanced therapies for sports medicine and severe burn care, markets three products: MACI® for knee cartilage repair, Epicel® for severe burns, and NexoBrid® for eschar removal.
03-03 13:30
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
MediWound Ltd. (Nasdaq: MDWD), a global leader in enzymatic therapeutics for tissue repair, will report its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026. The company will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the results. The conference call can be accessed via toll-free, local, or international numbers, with details provided. An archived webcast will be available on the Med...
02-19 13:00
MediWound to Present at Upcoming Investor Conferences
<p>MediWound Ltd. (Nasdaq: MDWD), a global leader in enzymatic therapeutics for tissue repair, announced that its management team will present at two upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, and the TD Cowen 46th Annual Health Care Conference on March 2, 2026. Both events will feature live webcasts accessible via the respective conference websites. For more details, visit...
02-17 13:00
